The benefits seen in people with early Alzheimer’s disease after a year of treatment with blarcamesine (Anavex 2-73)…
Michela Luciano, PhD
Michela Luciano is a Science Writer at BioNews. Originally from the picturesque mountain town of L’Aquila, Italy, Michela holds a PhD in Molecular Biology from the University of Salzburg, where her research focused on the role of inflammation in Acute Myeloid Leukemia. With a deep passion for scientific communication, Michela transitioned into her first role as Scientific Writer in 2022. Outside of work, Michela is a passionate photographer. She enjoys mountain hikes, running, and spending as much time as possible outdoors.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Michela Luciano, PhD
Health Canada has conditionally approved Leqembi (lecanemab) for certain adults with early Alzheimer’s disease, making it the first…